Immunotherapy employs patients' own immune systems to fight cancer, and it has shown itself to be an effective treatment in ...

Programmed death-1 (PD-1) inhibition with pembrolizumab led to durable remission in 31.3% of patients with early acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) relapse after ...

During a live event, Nataliya Mar, MD, discussed systemic therapies such as lenvatinib/pembrolizumab in advanced renal cell ...

Q2 2025 Earnings Call Transcript August 13, 2025 PDS Biotechnology Corporation beats earnings expectations. Reported EPS is $ ...

Potential for patient access and reimbursement/sale of Multikine in Saudi Arabia within approximately 60 days following ...

Cowboys owner Jerry Jones revealed he quietly battled stage 4 melanoma for over a decade, crediting experimental ...

Q1 2026 Earnings Call Transcript August 13, 2025 Aethlon Medical, Inc. misses on earnings expectations. Reported EPS is $-0.85 EPS, expectations were $-0.68. Operator: Good afternoon, and welcome to ...

Phase 1/1b clinical trial on track for interim data readout in the fourth quarter of 2025, including patients in both the ...

MSD's plan to reduce its headcount by around 6,000, first revealed a couple of weeks ago, looks like it will start at its ...

Discover insights into Aethlon Medical's Q1 2026 earnings as they advance their Australian oncology trial, cut costs by 32%, and focus on ...

Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the second quarter ...

Phase 1b/2 in MSS CRC shows 19.4-month median OS (mOS) in 10 mg/kg dose cohorts; mOS for 20 mg/kg cohorts has not yet been reached Alignment with FDA on Phase 2 and Phase 3 trial design elements.